GlassScriptPhysician profile
Chester J Maxson
NPI 1306928908
$3,076.78
in general payments reported to CMS, 2019-2025
20 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $82.90 · 2021: $807 · 2022: $208 · 2023: $39.28 · 2024: $644 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $897.95 | 2019-2025 | Watchman Flx, Axios, Exalt Model D |
| Medtronic, INC. | $628.30 | 2021-2022 | |
| Abbvie INC. | $582.11 | 2020-2025 | |
| Covidien LP | $142.56 | 2019 | |
| Phathom Pharmaceuticals, INC. | $139.57 | 2024 | Voquezna |
| Janssen Biotech, INC. | $136.92 | 2019-2025 | Tremfya |
| Genzyme Corporation | $117.74 | 2025 | |
| Ambu INC. | $112.55 | 2021 | |
| Btg International INC. | $91.08 | 2019 | |
| Intercept Pharmaceuticals, INC. | $39.68 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.24 | 2024 | Entyvio |
| Conmed Corporation | $27.53 | 2020 | |
| Ferring Pharmaceuticals INC. | $23.81 | 2025 | Clenpiq |
| Ironwood Pharmaceuticals, INC | $22.94 | 2023 | Linzess |
| Intuitive Surgical, INC. | $20.16 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $18.45 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $15.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.87 | 2021 | |
| Allergan, INC. | $12.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chester Maxson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.